(NASDAQ: CGEN) Compugen's forecast annual revenue growth rate of -24.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Compugen's revenue in 2026 is $74,001,000.On average, 7 Wall Street analysts forecast CGEN's revenue for 2026 to be $909,635,974, with the lowest CGEN revenue forecast at $201,951,879, and the highest CGEN revenue forecast at $1,653,031,072. On average, 7 Wall Street analysts forecast CGEN's revenue for 2027 to be $1,938,150,751, with the lowest CGEN revenue forecast at $37,131,865, and the highest CGEN revenue forecast at $4,897,427,796.
In 2028, CGEN is forecast to generate $2,983,431,702 in revenue, with the lowest revenue forecast at $1,346,030,115 and the highest revenue forecast at $5,113,777,746.